Patents Assigned to Amgen
  • FORMULATIONS
    Publication number: 20150315271
    Abstract: The invention provides a formulation comprising a buffer with a pH from about 4.0 to about 6.0, proline and an effective amount of a polypeptide. The polypeptide can be an antibody. The specification also provides methods of preparing the formulation, a kit containing the formulation and methods of using the formulation.
    Type: Application
    Filed: May 5, 2015
    Publication date: November 5, 2015
    Applicant: AMGEN INC.
    Inventors: Jaby JACOB, Masazumi MATSUMURA, Yatin GOKARN, David BREMS
  • Ferroportin antibodies and methods of use
    Patent number: 9175078
    Abstract: Compositions for treating disorders of iron homeostasis are provided. More particularly, anti-ferroportin antibodies, compositions containing such antibodies, corresponding nucleic acids, vectors and host cells, and methods of making such antibodies are provided.
    Type: Grant
    Filed: January 23, 2009
    Date of Patent: November 3, 2015
    Assignee: AMGEN INC.
    Inventors: Tara Arvedson, Gregory Dyas, James B. Rottman, Barbra Sasu, Xiao-juan Bi, Grace Ki Jeong Lee, Jackie Z. Sheng
  • Heterobicyclic compounds
    Patent number: 9174992
    Abstract: Heterobicyclic compounds of Formula (I): or a pharmaceutically-acceptable salt, tautomer, or stereoisomer thereof, as defined in the specification, and compositions containing them, and processes for preparing such compounds. Provided herein also are methods of treating disorders or diseases treatable by inhibition of PDE10, such as obesity, non-insulin dependent diabetes, schizophrenia, bipolar disorder, obsessive-compulsive disorder, Huntington's Disease, and the like.
    Type: Grant
    Filed: February 28, 2013
    Date of Patent: November 3, 2015
    Assignee: Amgen Inc.
    Inventors: Jennifer R. Allen, Albert Amegadzie, Kristin L. Andrews, James Brown, Jian J. Chen, Ning Chen, Essa Hu Harrington, Qingyian Liu, Thomas T. Nguyen, Alexander J. Pickrell, Wenyuan Qian, Shannon Rumfelt, Robert M. Rzasa, Chester Chenguang Yuan, Wenge Zhong
  • METHOD OF TREATING OR AMELIORATING METABOLIC DISORDERS USING GROWTH DIFFERENTIATION FACTOR 15 (GDF-15)
    Publication number: 20150307575
    Abstract: Methods of treating metabolic diseases and disorders using a GDF15 polypeptide are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy.
    Type: Application
    Filed: April 5, 2012
    Publication date: October 29, 2015
    Applicant: AMGEN INC.
    Inventor: YuMei Xiong
  • GLYCINE TRANSPORTER-1 INHIBITORS
    Publication number: 20150307457
    Abstract: The present invention provides compounds that are glycine transporter 1 (hereinafter referred to as GlyT-1) inhibitors and are therefore useful for the treatment of diseases treatable by inhibition of GlyT1 such as cognitive disorders associated with Schizophrenia, ADHD (attention deficit hyperactivity disorder), MCI (mild cognitive impairment), and the like. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.
    Type: Application
    Filed: April 29, 2014
    Publication date: October 29, 2015
    Applicant: AMGEN INC.
    Inventors: Stephen A. Hitchcock, Albert Amegadzie, Wenyuan Qian, Xiaoyang Xia, Scott S. Harried
  • CRYSTALLINE FORMS OF (1S)-1-[5-(AMINO)-1,2,4-THIADIAZOL-3-YL]ETHANE-1,2-DIOL
    Publication number: 20150299182
    Abstract: The present invention relates to crystalline polymorph forms of (1S)-1-[5-({3-[(2-methylpyridin-3-yl)oxy]-5-(pyridin-2-ylsulfanyl)pyridin-2-yl}amino)-1,2,4-thiadiazol-3-yl]ethane-1,2-diol, to pharmaceutical compositions comprising such crystalline polymorph forms, and to processes for preparing them. The invention further relates to methods of treatment of diabetes related disorders comprising administering such solid-state forms or compositions thereof to a subject, and to use of such crystalline polymorph forms in the manufacture of medicaments.
    Type: Application
    Filed: November 8, 2013
    Publication date: October 22, 2015
    Applicants: Amgen Inc., Array BioPharma Inc.
    Inventors: Sylvie Asselin, Lisa Brett, Ying Chen, Donald T. Corson, Andrew Cosbie, Robert Farrell, Indrani W. Gunawardana, Jinkun Huang, Jonathan W. Lane, Dennis Lei, Christopher M. Lindemann, Van Luu, Coralee G. Mannila, Robert Milburn, Henry Morrison, Helming Tan, Jason Tedrow, Daniel J. Watson
  • DRUG DELIVERY DEVICE
    Publication number: 20150290390
    Abstract: A drug delivery device includes a blunt cannula and a reservoir. The blunt cannula has a cylindrical wall that defines an axial passage between a first end and a second end of the blunt cannula. The wall has at least a first tapered region at the first end to define an opening in fluid communication with the axial passage and adapted at the first end to resist interruption of fluid flow through the axial passage and out of the first end of the blunt cannula. The reservoir is connected to the second end of the blunt cannula.
    Type: Application
    Filed: November 20, 2013
    Publication date: October 15, 2015
    Applicant: AMGEN INC.
    Inventors: Lawrence Ring, Dhairya Mehta, Stephanie Toy, Ferry Tamtoro, Alexander Stuart Cairns, Scott R. Gibson
  • Apelin antigen-binding proteins and uses thereof
    Patent number: 9156911
    Abstract: This disclosure relates to apelin antigen-binding proteins and methods of using the apelin antigen-binding proteins. The antigen-binding protein may comprise an antibody to apelin and can be used to treat pathological conditions involving angiogenesis. The pathological conditions can comprise cancer or retinopathy and/or retinopathy-related complications.
    Type: Grant
    Filed: July 17, 2012
    Date of Patent: October 13, 2015
    Assignee: AMGEN INC.
    Inventors: Shu-Chen Lu, Minghan Wang
  • Predictive biomarker of survival in the treatment of renal cell carcinoma
    Patent number: 9151761
    Abstract: Methods and compositions are disclosed for predicting and treating the clinical benefit to a human renal cell carcinoma patient prior to their treatment with a VEGFR inhibitor and an Ang2 inhibitor.
    Type: Grant
    Filed: June 28, 2012
    Date of Patent: October 6, 2015
    Assignee: Amgen Inc.
    Inventors: Abraham Antonio Anderson, David M. Weinreich
  • Binding molecules for BCMA and CD3
    Patent number: 9150664
    Abstract: The present invention relates to a binding molecule comprising a first and a second binding domain, wherein the first binding domain is capable of binding to epitope clusters of BCMA, and the second binding domain is capable of binding to the T cell CD3 receptor complex. Moreover, the invention provides a nucleic acid sequence encoding the binding molecule, a vector comprising said nucleic acid sequence and a host cell transformed or transfected with said vector. Furthermore, the invention provides a process for the production of the binding molecule of the invention, a medical use of said binding molecule and a kit comprising said binding molecule.
    Type: Grant
    Filed: November 15, 2012
    Date of Patent: October 6, 2015
    Assignees: AMGEN RESEARCH (MUNICH) GMBH, BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Peter Kufer, Tobias Raum, Patrick Hoffmann, Roman Kischel, Ralf Lutterbuese, Doris Rau, Paul Adam, Eric Borges, Barbara Hebeis, Susanne Hipp
  • Thrombopoietic compounds
    Patent number: 9145450
    Abstract: The invention relates to the field of compounds, especially peptides or polypeptides, that have thrombopoietic activity. The peptides and polypeptides of the invention may be used to increase platelets or platelet precursors (e.g., megakaryocytes) in a mammal.
    Type: Grant
    Filed: January 19, 2006
    Date of Patent: September 29, 2015
    Assignee: AMGEN INC.
    Inventors: Chuan-Fa Liu, Ulrich Feige, Janet C. Cheetham
  • Sclerostin antibody crystals and formulations thereof
    Patent number: 9145457
    Abstract: Described herein are anti-sclerostin antibody crystals, methods of making such antibody crystals and formulations comprising the antibody crystals.
    Type: Grant
    Filed: March 23, 2012
    Date of Patent: September 29, 2015
    Assignee: AMGEN INC.
    Inventors: Christi L. Clogston, Twinkle R. Christian, Timothy David Osslund, Elisabeth Freeman
  • Peptides and related molecules that bind to TALL-1
    Patent number: 9139645
    Abstract: The present invention concerns therapeutic agents that modulate the activity of TALL-1. In accordance with the present invention, modulators of TALL-1 may comprise an amino acid sequence Dz2Lz4 wherein z2 is an amino acid residue and z4 is threonyl or isoleucyl. Exemplary molecules comprise a sequence of the formulae (SEQ. ID. NO: 100) a1a2a3CDa6La8a9a10Ca12a13a14, (SEQ. ID. NO: 104) b1b2b3Cb5b6Db8Lb10b11b12b13b14Cb16b17b18 (SEQ. ID. NO: 105) c1c2c3Cc5Dc7Lc9c10c11c12c13c14Cc16c17c18 (SEQ. ID. NO: 106) d1d2d3Cd5d6d7WDd10Ld13d14d15Ld16d17d18 (SEQ. ID. NO: 107) e1e2e3Ce5e6e7De9Le11Ke13Ce15e16e17e18 (SEQ. ID NO: 109) f1f2f3Kf5Df7Lf9f10Qf12f13f14 wherein the substituents are as defined in the specification.
    Type: Grant
    Filed: July 9, 2013
    Date of Patent: September 22, 2015
    Assignee: Amgen Inc.
    Inventors: Hosung Min, Hailing Hsu, Fei Xiong
  • AMINO-DIHYDROTHIAZINE AND AMINO-DIOXIDO DIHYDROTHIAZINE COMPOUNDS AS BETA-SECRETASE ANTAGONISTS AND METHODS OF USE
    Publication number: 20150259308
    Abstract: The present invention provides a new class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula I: wherein variables A4, A5, A6, A8, R1, R2, R3, R7 and n of Formula I, independently, are defined herein. The invention also provides pharmaceutical compositions comprising the compounds, and corresponding uses of the compounds and compositions for treatment of disorders and/or conditions related to A-beta plaque formation and deposition, resulting from the biological activity of BACE. Such BACE mediated disorders include, for example, Alzheimer's Disease, cognitive deficits, cognitive impairments, schizophrenia and other central nervous system conditions. The invention further provides compounds of Formula II and sub-formula embodiments thereof, intermediates and processes and methods useful for the preparation of compounds of Formulas I-II.
    Type: Application
    Filed: October 10, 2013
    Publication date: September 17, 2015
    Applicant: AMGEN INC.
    Inventors: Richard T. Lewis, Jennifer R. Allen, Yuan Cheng, Deborah Choquette, Oleg Epstein, Angel Guzman-Perez, Paul E. Harrington, Zihao Hua, Randall W. Hungate, Jason Brooks Human, Ted Judd, Qingyian Liu, Patricia Lopez, Ana Elena Minatti, Philip Olivieri, Karina Romero, Shannon Rumfelt, Robert M. Rzasa, Laurie Schenkel, John Stellwagen, Ryan White, Qiufen Xue, Xiao Mei Zheng, Wenge Zhong
  • Bispecific binding agents
    Patent number: 9133272
    Abstract: The invention relates to bispecific anti-sclerostin/anti-DKK1 binding agents and combinations of anti-sclerostin and anti-DKK1 binding agents, and related methods of treatment.
    Type: Grant
    Filed: February 29, 2012
    Date of Patent: September 15, 2015
    Assignee: AMGEN INC.
    Inventors: Monica Florio, Taruna Arora, Christopher J. R. Paszty, William G. Richards
  • Method for culturing mammalian cells to improve recombinant protein production
    Patent number: 9133493
    Abstract: The present invention relates to methods for mammalian cell culture. The methods make use of independent tyrosine and cystine feed streams.
    Type: Grant
    Filed: April 20, 2012
    Date of Patent: September 15, 2015
    Assignee: AMGEN INC.
    Inventors: Matthew I. Jerums, Amanda Kano, Henry Lin, Shun Luo, Jian Wu, Rebecca E. McCoy, Arvia E. Morris
  • Aurora kinase modulators and methods of use
    Patent number: 9126935
    Abstract: The present invention relates to chemical compounds having a general formula I wherein A1-6, L1, R1, R4-6 and n are defined herein, and synthetic intermediates, which are capable of modulating various protein kinase receptor enzymes and, thereby, influencing various disease states and conditions related to the activities of such kinases. For example, the compounds are capable of modulating Aurora kinase thereby influencing the process of cell cycle and cell proliferation to treat cancer and cancer-related diseases. The invention also includes pharmaceutical compositions, including the compounds and methods of treating disease states related to the activity of Aurora kinase.
    Type: Grant
    Filed: August 7, 2009
    Date of Patent: September 8, 2015
    Assignee: Amgen Inc.
    Inventors: Holly L. Deak, Brian L. Hodous, Jason B. Human, Hanh Nho Nguyen, Karina Romero
  • Benzimidazole and azabenzimidazole compounds that inhibit anaplastic lymphoma kinase
    Patent number: 9115127
    Abstract: Compounds of Formula (I) are useful inhibitors of anaplastic lymphoma kinase. Compounds of Formula (I) have the following structure: where the definitions of the variables are provided herein.
    Type: Grant
    Filed: July 28, 2011
    Date of Patent: August 25, 2015
    Assignee: AMGEN INC.
    Inventors: Christiane M. Boezio, Alan C. Cheng, Deborah Choquette, Richard T. Lewis, Michele H. Potashman, Karina Romero, John C. Stellwagen, Douglas A. Whittington
  • Modified Fc molecules
    Patent number: 9114175
    Abstract: Disclosed is a process for preparing a pharmacologically active compound, in which at least one internal conjugation site of an Fc domain sequence is selected that is amenable to conjugation of an additional functional moiety by a defined conjugation chemistry through the side chain of an amino acid residue at the conjugation site. An appropriate amino acid residue for conjugation may be present in a native Fc domain at the conjugation site or may be added by insertion (i.e., between amino acids in the native Fc domain) or by replacement (i.e., removing amino acids and substituting different amino acids). In the latter case, the number of amino acids added need not correspond to the number of amino acids removed from the previously existing Fc domain. This technology may be used to produce useful compositions of matter and pharmaceutical compositions containing them.
    Type: Grant
    Filed: June 28, 2011
    Date of Patent: August 25, 2015
    Assignee: AMGEN INC.
    Inventors: Colin V. Gegg, Kenneth W. Walker, Leslie P. Miranda, Fei Xiong
  • CARRIER IMMUNOGLOBULINS AND USES THEREOF
    Publication number: 20150232566
    Abstract: Disclosed is an isolated immunoglobulin. Also disclosed are pharmaceutical compositions and medicaments comprising the immunoglobulin, isolated nucleic acid encoding it, vectors, host cells, useful in methods of making it. In some embodiments the immunoglobulin comprises one to twenty-four pharmacologically active chemical moieties conjugated thereto, such as a pharmacologically active polypeptide.
    Type: Application
    Filed: February 20, 2015
    Publication date: August 20, 2015
    Applicant: AMGEN INC.
    Inventors: Kenneth W. WALKER, Frederick W. JACOBSEN, Taruna Arora